{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:11:24Z","timestamp":1789506684190,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010211","name":"Education Department of Jilin Province","doi-asserted-by":"publisher","award":["JJKH20200452KJ"],"award-info":[{"award-number":["JJKH20200452KJ"]}],"id":[{"id":"10.13039\/501100010211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011789","name":"Jilin Provincial Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128758","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:04:24Z","timestamp":1781107464000},"page":"128758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Autologous tumor lysate vaccines enhance anti-glioma immunity and prolong survival in a GL261 glioblastoma mouse model"],"prefix":"10.1016","volume":"88","author":[{"given":"Boqi","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoguo","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianmin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2026.128758_bb0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12964-023-01098-0","article-title":"Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma","volume":"21","author":"Zhao","year":"2023","journal-title":"Cell Commun Signal"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128758_bb0010","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nature Cancer"},{"key":"10.1016\/j.vaccine.2026.128758_bb0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fimmu.2020.583287","article-title":"A roadmap toward the definition of actionable tumor-specific antigens","volume":"11","author":"Minati","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128758_bb0020","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s00262-018-2157-5","article-title":"Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer","volume":"67","author":"Rojas-Sep\u00falveda","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2026.128758_bb0025","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00262-020-02496-w","article-title":"Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients","volume":"69","author":"Wang","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2026.128758_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1166169","article-title":"Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells","volume":"14","author":"Saleh","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128758_bb0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004646","article-title":"Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors","volume":"10","author":"Kalinovsky","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128758_bb0040","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2174\/1389201022666210719164538","article-title":"Erythrocyte-cancer hybrid membrane-camouflaged mesoporous silica nanoparticles loaded with gboxin for glioma-targeting therapy","volume":"23","author":"Jiao","year":"2022","journal-title":"Curr Pharm Biotechnol"},{"issue":"Supplement_5","key":"10.1016\/j.vaccine.2026.128758_bb0045","doi-asserted-by":"crossref","first-page":"v145","DOI":"10.1093\/neuonc\/noad179.0550","article-title":"IMMU-18. Establishment of CAR-NK cell therapy targeting B7-H3 against glioblastoma","volume":"25","author":"Tachi","year":"2023","journal-title":"Neuro-Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2026.128758_bb0050","doi-asserted-by":"crossref","first-page":"ii8","DOI":"10.1093\/neuonc\/noab180.026","article-title":"OS06. 2A local immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors in combination with CAR-NK cells","volume":"23","author":"Strecker","year":"2021","journal-title":"Neuro-Oncol"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128758_bb0055","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.4049\/jimmunol.166.12.7370","article-title":"Immunotherapy of melanoma: a dichotomy in the requirement for IFN-\u03b3 in vaccine-induced antitumor immunity versus adoptive immunotherapy","volume":"166","author":"Winter","year":"2001","journal-title":"The Journal of Immunology"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128758_bb0060","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.128758_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.726421","article-title":"Microglia and perivascular macrophages act as antigen presenting cells to promote CD8 T cell infiltration of the brain","volume":"12","author":"Goddery","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128758_bb0070","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2326-6066.CIR-22-0098","article-title":"The conventional dendritic cell 1 subset primes CD8+ T cells and traffics tumor antigen to drive antitumor immunity in the brain","volume":"11","author":"Bowman-Kirigin","year":"2023","journal-title":"Cancer Immunol Res"},{"issue":"6651","key":"10.1016\/j.vaccine.2026.128758_bb0075","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1126\/science.adi5711","article-title":"Channeling antigens to CD8+ T cells","volume":"380","author":"Rawat","year":"2023","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128758_bb0080","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/2326-6066.CIR-22-0494","article-title":"Inhibitor of apoptosis proteins antagonist induces T-cell proliferation after cross-presentation by dendritic cells","volume":"11","author":"Hoefsmit","year":"2023","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128758_bb0085","article-title":"CD86 is associated with immune infiltration and immunotherapy signatures in AML and promotes its progression","volume":"2023","author":"Zhang","year":"2023","journal-title":"J Oncol"},{"key":"10.1016\/j.vaccine.2026.128758_bb0090","series-title":"Personalized neoantigen-pulsed autologous dendritic cells vaccine as an adjuvant treatment for patients with newly-diagnosed glioblastoma multiforme: a phase I trial","first-page":"e14025","author":"Zhang","year":"2024"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128758_bb0095","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1158\/2326-6066.CIR-23-0721","article-title":"Machine learning\u2013directed conversion of glioblastoma cells to dendritic cell\u2013like antigen-presenting cells as cancer immunotherapy","volume":"12","author":"Liu","year":"2024","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128758_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101421","article-title":"An anti-CD19\/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80\/86-upregulated DLBCL","volume":"5","author":"Prinz","year":"2024","journal-title":"Cell Reports Medicine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128758_bb0105","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","article-title":"Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma","volume":"12","author":"Agliardi","year":"2021","journal-title":"Nat Commun"},{"issue":"14","key":"10.1016\/j.vaccine.2026.128758_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202308280","article-title":"RWTC-MBTA vaccine induces potent adaptive immune responses against glioblastomas via dynamic activation of dendritic cells","volume":"11","author":"Wang","year":"2024","journal-title":"Adv Sci"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128758_bb0115","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/neuonc\/noac138","article-title":"Dysfunctional dendritic cells limit antigen-specific T cell response in glioma","volume":"25","author":"Friedrich","year":"2023","journal-title":"Neuro-oncology"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128758_bb0120","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41467-023-35957-8","article-title":"Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma","volume":"14","author":"Zhou","year":"2023","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128758_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15102430","article-title":"Dendritic cells pulsed with tumor lysates induced by tetracyanotetra (aryl) porphyrazines-based photodynamic therapy effectively trigger anti-tumor immunity in an orthotopic mouse glioma model","volume":"15","author":"Redkin","year":"2023","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128758_bb0130","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87059","article-title":"PD-1 blockade enhances the vaccination-induced immune response in glioma","volume":"1","author":"Antonios","year":"2016","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128758_bb0135","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7150\/jca.12899","article-title":"Delivery system of CpG oligodeoxynucleotides through eliciting an effective T cell immune response against melanoma in mice","volume":"7","author":"Sun","year":"2016","journal-title":"J Cancer"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128758_bb0140","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.148990","article-title":"Immune landscape of a genetically engineered murine model of glioma compared with human glioma","volume":"7","author":"Zamler","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128758_bb0145","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41467-023-36430-2","article-title":"FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells","volume":"14","author":"Zhao","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128758_bb0150","first-page":"1","article-title":"Functional virus-specific memory T cells survey glioblastoma","author":"Ning","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128758_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009486","article-title":"EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses","volume":"12","author":"Lertsumitkul","year":"2024","journal-title":"J Immunother Cancer"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:38:18Z","timestamp":1789504698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26005670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S0264410X26005670"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128758","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autologous tumor lysate vaccines enhance anti-glioma immunity and prolong survival in a GL261 glioblastoma mouse model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128758","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128758"}}